6-(2-Aminoethoxy)-3-methyl-2-phenyl-1H-indole | 372093-76-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 6-(2-Aminoethoxy)-3-methyl-2-phenyl-1H-indole
• 英文别名: 2-[(3-methyl-2-phenyl-1H-indol-6-yl)oxy]ethanamine
• CAS: 372093-76-0
• 化学式: C₁₇H₁₈N₂O
• 分子量: 266.343
• InChiKey: IRLPPNKHOTYVOQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  51
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• TROPAN COMPOUND
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1785421A1

  公开（公告）日：2007-05-16

  The conventional anticholinergic drugs for administration through inhalation have been considered to have the possibility of aggravating dysuria associated with prostatic hyperplasia mediated by blood, and it has been demanded that the conventional anticholinergic drugs for administration through inhalation will have to show reduced side effects or adverse ractions. The present invention relates to a compound represented by the general formula (I): (wherein A represents; and R1, R2, R3 and R1 each a hydrogen atom or a substituent; R5 is a substituent; X- is an anion;the symbol: denotes an exo-form or endo-form, or their mixture), its salt or solvation product thereof. They are useful as a prophylactic and/or therapeutic agent with reduced side effects or adverse reactions for the diseases mediated by the muscarinic receptor.

  传统的抗胆碱药物通过吸入给药被认为可能加重与前列腺增生相关的排尿困难，并要求传统的抗胆碱药物通过吸入给药必须显示减少副作用或不良反应。 本发明涉及一种由通式（I）表示的化合物： （其中A代表; 和R1、R2、R3和R1分别是氢原子或取代基; R5是取代基; X-是阴离子;符号: 表示外向型或内向型，或它们的混合物），其盐或溶剂化产物。它们可用作通过胆碱受体介导的疾病的预防和/或治疗剂，具有减少副作用或不良反应。
• Novel bicyclic compounds
  申请人：——

  公开号：US20030191174A1

  公开（公告）日：2003-10-09

  Compounds of the general formula (I): 1 or a salt thereof, wherein R 1 is hydrogen, hydroxyl or halogen; R 2 is NHSO 2 CH 3 , SO 2 NHCH 3 or the like; R 5 and R 6 each independently is hydrogen, C 1-6 alkyl, optionally substituted phenyl or optionally substituted benzyl; X is NH, sulfur, oxygen or methylene; Y is oxygen, NR 7 , sulfur, methylene or a bond; and * represents an asymmetric carbon atom. The compounds are useful as a medicine for treating or preventing diabetes, obesity, hyperlipidemia, digestive diseases, depression or urinary disturbances.

  通式（I）的化合物：1或其盐，其中R1是氢、羟基或卤素；R2是NHSO2CH3、SO2NHCH3或类似物；R5和R6各自独立地是氢、C1-6烷基、可选择取代的苯基或可选择取代的苄基；X是NH、硫、氧或亚甲基；Y是氧、NR7、硫、亚甲基或键；*代表一个不对称的碳原子。这些化合物可用作治疗或预防糖尿病、肥胖症、高脂血症、消化系统疾病、抑郁症或尿路紊乱的药物。
• NOVEL BICYCLIC COMPOUNDS
  申请人：Asahi Kasei Kabushiki Kaisha

  公开号：EP1277736A1

  公开（公告）日：2003-01-22

  Compounds of the general formula (I): or a salt thereof, wherein R1 is hydrogen, hydroxyl or halogen; R2 is NHSO2CH3, SO2NHCH3 or the like; R5 and R6 each independently is hydrogen, C1-6 alkyl, optionally substituted phenyl or optionally substituted benzyl; X is NH, sulfur, oxygen or methylene; Y is oxygen, NR7, sulfur, methylene or a bond; and * represents an asymmetric carbon atom. The compounds are useful as a medicine for treating or preventing diabetes, obesity, hyperlipidemia, digestive diseases, depression or urinary disturbances.

  通式（I）的化合物： 或其盐，其中 R1 是氢、羟基或卤素；R2 是 NHSO2CH3、SO2NHCH3 或类似物；R5 和 R6 各自独立地是氢、C1-6 烷基、任选取代的苯基或任选取代的苄基；X 是 NH、硫、氧或亚甲基；Y 是氧、NR7、硫、亚甲基或键；* 代表不对称碳原子。 这些化合物可用作治疗或预防糖尿病、肥胖症、高脂血症、消化系统疾病、抑郁症或泌尿系统紊乱的药物。
• US6861444B2
  申请人：——

  公开号：US6861444B2

  公开（公告）日：2005-03-01
• US7049445B2
  申请人：——

  公开号：US7049445B2

  公开（公告）日：2006-05-23